抗白细胞介素-5单克隆抗体治疗哮喘效果的Meta分析

Meta-Analysis on Effect of Anti-Interleukin-5 Monoclonal Antibody Therapy for Asthma

目的:系统评价抗白细胞介素-5(IL-5)单克隆抗体治疗哮喘的临床效果。方法:在PubMed、Embase和Cochrane对照试验中央注册中心检索有关抗IL-5单克隆抗体治疗哮喘的随机对照试验文献,检索时间为截至2024年3月,对数据采用CMA 2.0软件进行Meta分析。结果:纳入21篇文献,共8717例患者,试验组4593例,对照组4124例。Meta分析结果显示,在第1秒用力呼气容积(FEV1)、哮喘生活质量问卷评分、不良事件发生情况方面,试验组优于对照组。结论:抗IL-5单克隆抗体治疗哮喘的临床效果较好,可改善患者FEV1、生活质量,且安全性较高。

Objective:To systematically evaluate the clinical effects of anti-interleukin-5(IL-5)monoclonal antibody therapy for asthma.Methods:A retrieval for randomized controlled trials of anti-IL-5 monoclonal antibody therapy for asthma was performed in PubMed,Embase,and Cochrane Central Register of Controlled Trials as of March 2024.Meta-analysis of data was performed using CMA 2.0 software.Results:A total of 21 literatures were included,involving 8717 patients.There were 4593 patients in the experimental group and 4124 patients in the control group.Meta-analysis results showed that forced expiratory volume in 1 second(FEV1),asthma quality of life questionnaire score,and occurrence of adverse events in the experimental group were better than those in the control group.Conclusion:Anti-IL-5 monoclonal antibody has a good clinical effect in the treatment of asthma,and can improve the FEV1 and quality of life of patients,and has a high safety profile.